ID   M202
AC   CVCL_D746
DR   cancercelllines; CVCL_D746
DR   Cosmic; 1425343
DR   Cosmic; 1459667
DR   Cosmic; 1665002
DR   Wikidata; Q54903517
RX   PubMed=20406486;
RX   PubMed=20689758;
RX   PubMed=22515704;
RX   PubMed=25645078;
RX   PubMed=28196595;
WW   https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   Doubling time: 26.1 hours (PubMed=20406486).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=20406486; PubMed=25645078).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (PubMed=20406486; PubMed=25645078).
CC   Omics: Protein expression by reverse-phase protein arrays.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 05-10-23; Version: 12
//
RX   PubMed=20406486; DOI=10.1186/1479-5876-8-39;
RA   Sondergaard J.N., Nazarian R., Wang Q., Guo D.-L., Hsueh T., Mok S.,
RA   Sazegar H., MacConaill L.E., Barretina J.G., Kehoe S.M., Attar N.,
RA   von Euw E.M., Zuckerman J.E., Chmielowski B., Comin-Anduix B.,
RA   Koya R.C., Mischel P.S., Lo R.S., Ribas A.;
RT   "Differential sensitivity of melanoma cell lines with BRAFV600E
RT   mutation to the specific Raf inhibitor PLX4032.";
RL   J. Transl. Med. 8:39.1-39.11(2010).
//
RX   PubMed=20689758; DOI=10.1593/neo.10414;
RA   Tap W.D., Gong K.-W., Dering J., Tseng Y., Ginther C., Pauletti G.,
RA   Glaspy J.A., Essner R., Bollag G., Hirth P., Zhang C., Slamon D.J.;
RT   "Pharmacodynamic characterization of the efficacy signals due to
RT   selective BRAF inhibition with PLX4032 in malignant melanoma.";
RL   Neoplasia 12:637-649(2010).
//
RX   PubMed=22515704; DOI=10.1186/1476-4598-11-22;
RA   von Euw E.M., Atefi M., Attar N., Chu C., Zachariah S., Burgess B.L.,
RA   Mok S., Ng C., Wong D.J.L., Chmielowski B., Lichter D.I., Koya R.C.,
RA   McCannel T.A., Izmailova E., Ribas A.;
RT   "Antitumor effects of the investigational selective MEK inhibitor
RT   TAK733 against cutaneous and uveal melanoma cell lines.";
RL   Mol. Cancer 11:22.1-22.9(2012).
//
RX   PubMed=25645078; DOI=10.1186/s12943-015-0293-5;
RA   Atefi M., Titz B., Avramis E., Ng C., Wong D.J.L., Lassen A.,
RA   Cerniglia M., Escuin-Ordinas H., Foulad D., Comin-Anduix B.,
RA   Graeber T.G., Ribas A.;
RT   "Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.";
RL   Mol. Cancer 14:27.1-27.12(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//